citalopram has been researched along with Biological Clock Disturbances in 1 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allison, KC | 1 |
| Studt, SK | 1 |
| Berkowitz, RI | 1 |
| Hesson, LA | 1 |
| Moore, RH | 1 |
| Dubroff, JG | 1 |
| Newberg, A | 1 |
| Stunkard, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Brain Imaging and Treatment Studies of the Night Eating Syndrome[NCT01401595] | Phase 3 | 87 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Outcome of treatment will be measured by self report questionnaire, the Night Eating Symptom Scale ( higher score indicates worse symptoms). The percentage of calories consumed after dinner was estimated by recall at each treatment visit, as compared to their baseline % of intake after dinner, which was calculated through food diaries. The number of nocturnal ingestions (waking during the night and eating) per week was also recalled at each treatment visit. (NCT01401595)
Timeframe: 12 weeks
| Intervention | percentage of calories after dinner (Mean) | |
|---|---|---|
| baseline %calories consumed after dinner | treatment end %calories after dinner | |
| Controls | 11.8 | NA |
| Night Eating Syndrome Open Label Escitalopram Treatment | 46.1 | 17.4 |
"The responses on the Night Eating Symptom Scale (NESS) will be examined over time.~Subjects will complete the NESS at their baseline visit, and at every treatment visit thereafter. The Night Eating Symptom Scale-II (NESS-II) (Lundgren, Allison, Vinai, & Gluck, 2012) is a 14-item questionnaire (possible range of 0-56, with higher scores indicating more severe symptoms) that assesses the presence of NES features over the course of the previous week. The NESS will indicate whether or not escitalopram is having an effect on our participants' night eating symptoms." (NCT01401595)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline Night Eating Symptom Scale | treatment end night eating symptom scale | |
| Controls | NA | NA |
| Night Eating Syndrome Open Label Escitalopram Treatment | 30.2 | 15.2 |
Number of nocturnal ingestions (waking and having something to eat) were reported at each visit. (NCT01401595)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| baseline nocturnal ingestions/week | treatment end nocturnal ingestions/week | |
| Controls | 0.0 | NA |
| Night Eating Syndrome Open Label Escitalopram Treatment | 5.8 | 1.2 |
1 other study available for citalopram and Biological Clock Disturbances
| Article | Year |
|---|---|
An open-label efficacy trial of escitalopram for night eating syndrome.
Topics: Adult; Chronobiology Disorders; Citalopram; Feeding and Eating Disorders; Female; Humans; Hyperphagi | 2013 |